Treatment with PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia Lowers Plasma Levels of Platelet-Activating Factor and Its Precursors: A Combined Metabolomic and Lipidomic Approach

Introduction: Familial hypercholesterolemia (FH) is characterized by extremely high levels of circulating low-density lipoprotein cholesterol (LDL-C) and is caused by mutations of genes involved in LDL-C metabolism, including LDL receptor (LDLR), apolipoprotein B (APOB), or proprotein convertase sub...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Minno, Alessandro, Orsini, Roberta Clara, Chiesa, Mattia, Cavalca, Viviana, Calcaterra, Ilenia, Tripaldella, Maria, Anesi, Andrea, Fiorelli, Susanna, Eligini, Sonia, Colombo, Gualtiero I., Tremoli, Elena, Porro, Benedetta, Di Minno, Matteo Nicola Dario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8391636/
https://www.ncbi.nlm.nih.gov/pubmed/34440277
http://dx.doi.org/10.3390/biomedicines9081073

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8391636/
https://www.ncbi.nlm.nih.gov/pubmed/34440277
http://dx.doi.org/10.3390/biomedicines9081073

Ejemplares similares